m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03682)
Name
PRX-111
Synonyms
FSH variants (female infertility), Protalix Biotherapeutics/ Compugen; Follicle stimulating hormone variants (female infertility), Protalix Biotherapeutics/ Compugen
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D08MVV
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Follicle-stimulating hormone receptor (FSHR)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Follicle-stimulating hormone receptor (FSHR) is a therapeutic target for PRX-111. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of PRX-111 through regulating the expression of Follicle-stimulating hormone receptor (FSHR). [1], [2]
References
Ref 1 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253).